<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00560066</url>
  </required_header>
  <id_info>
    <org_study_id>V58P14</org_study_id>
    <secondary_id>2007-002872-32</secondary_id>
    <nct_id>NCT00560066</nct_id>
  </id_info>
  <brief_title>Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions</brief_title>
  <official_title>A Phase IV, Multi-Center, Active-Controlled, Observer-Blind Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture (Optaflu®) or in Embryonated Hen Eggs (Agrippal®) in Adults and Elderly With and Without Underlying Medical Conditions, and to Evaluate the Immunogenicity in a Subset of Subjects With Underlying Medical Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Evaluation of the safety of Trivalent Subunit Influenza Vaccine Produced either in Mammalian
      Cell Culture or in embryonated Hen Eggs in subjects 18 years of age and above with and
      without underlying medical conditions and evaluation of the immunogenicity in a subset of
      subjects with underlying medical conditions, compared to an egg-based vaccine in a post
      marketing setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Reported At Least One Reactogenicity Sign After One Vaccination of TIV or cTIV</measure>
    <time_frame>From Day 1 up to and including Day 7 post-vaccination</time_frame>
    <description>Safety was assessed as the number of all subjects who reported at least one sign of reactogenicity after one vaccination of egg-derived (TIV) or cell culture-derived (cTIV) influenza virus vaccine from Day 1 through Day 7 post-vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Healthy Adults and Elderly Who Reported Solicited Local and Systemic Adverse Events (AEs) After One Vaccination of TIV or cTIV</measure>
    <time_frame>From Day 1 through Day 7 post-vaccination</time_frame>
    <description>Analysis was performed on a subset of safety population which included the healthy adults (≥18 to ≤60 years) and elderly (≥61 years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adults and Elderly With Underlying Medical Conditions Who Reported Solicited Local and Systemic Adverse Events After One Vaccination of TIV or cTIV</measure>
    <time_frame>From Day 1 through Day 7 post-vaccination</time_frame>
    <description>Analysis was performed on a subset of safety population which included the adults (≥18 to ≤60 years) and elderly (≥61 years) with underlying medical conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages Of Subjects With Underlying Medical Conditions Who Achieved Hemagglutination Inhibition (HI) Titer ≥40 After One Vaccination of TIV or cTIV</measure>
    <time_frame>Before vaccination (Day 1) and three weeks after vaccination (Day 22)</time_frame>
    <description>Immunogenicity was measured as the percentage of adults (≥18 to ≤60 years) and elderly (≥61 years) achieving HI titers ≥40 at baseline (Day 1) and three weeks (Day 22) after one vaccination of TIV or cTIV for each of three vaccine strains, evaluated using hemagglutination inhibition (HI) egg-derived antigen assay. This criterion is met according to European (CHMP) guideline if the percentage of subjects achieving HI titers ≥40 is &gt;70% (≥18 to ≤60 years), or &gt;60% (≥61 years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages Of Subjects Who Achieved Seroconversion Or Significant Increase In HI Titers After One Vaccination of TIV or cTIV</measure>
    <time_frame>Three weeks post-vaccination (Day 22)</time_frame>
    <description>Seroconversion or significant increase in HI titer as per CHMP criteria for each of the three strains is defined as the percentage of subjects with a prevaccination HI titer &lt;10 to a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, a ≥4-fold increase in postvaccination HI antibody titer. According to the CHMP criteria, the percentage of subjects achieving seroconversion/significant increase should be &gt;40% (≥18 to ≤60 years) or &gt;30% (≥61 years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Subjects With Underlying Medical Conditions After One Vaccination of TIV or cTIV</measure>
    <time_frame>Before vaccination (Day 1) and three weeks after vaccination (Day 22)</time_frame>
    <description>Immunogenicity was measured as HI geometric mean titers (GMTs) of subjects with underlying conditions, directed against each of three vaccine strains at baseline (Day 1) and three weeks after vaccination (Day 22) in adults (≥18 to ≤60 years) and elderly (≥61 years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio of Subjects With Underlying Medical Conditions After One Vaccination of TIV or cTIV</measure>
    <time_frame>Three weeks post-vaccination (Day 22)</time_frame>
    <description>Immunogenicity was measured as the geometric mean ratio (GMR), calculated as the ratio of postvaccination to prevaccination HI GMTs for each of the three strains, three weeks after one vaccination (Day 22) of TIV or cTIV. CHMP criteria is considered fulfilled for each of the three strains if the geometric mean increase GMR (Day 22/Day 1) in HI antibody titer is &gt;2.5 (≥18 to ≤60 years) or &gt;2.0 (≥61 Years).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1398</enrollment>
  <condition>Seasonal Influenza</condition>
  <condition>Vaccine</condition>
  <arm_group>
    <arm_group_label>cTIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one vaccination of cell culture-derived influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received one vaccination of egg-derived influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell-derived influenza vaccine</intervention_name>
    <description>1 dose of 0.5 mL in the deltoid region of the non-dominant arm</description>
    <arm_group_label>cTIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Egg-derived influenza vaccine</intervention_name>
    <description>1 dose of 0.5 mL in the deltoid region of the non-dominant arm</description>
    <arm_group_label>TIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects 18 years of age and above, mentally competent, willing and able to give
             informed consent prior to study entry;

          2. Able to comply with all study procedures and requirements.

        Exclusion Criteria:

          1. History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to any
             vaccine component;

          2. Fatal prognosis of an underlying medical condition (&lt;12 months life expectancy);

          3. History of Guillain-Barre syndrome;

          4. Bleeding diathesis or receiving anticoagulants of the coumarin type;

          5. Hospitalization or residence in a nursing care facility;

          6. Planned to receive seasonal influenza vaccine outside of this study;

          7. Receipt of another vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for
             live vaccines) prior to enrollment in this study;

          8. Fever (defined as axillary temperature ≥38.0°C) or any acute illness within 3 days
             prior to study vaccination;

          9. Receipt of another investigational agent within 30 days prior to enrollment in the
             study or before completion of the safety follow-up period in another study, whichever
             is longer, and unwilling to refuse participation in another clinical study through the
             end safety follow up period of the study;

         10. Any condition, which, in the opinion of the investigator, might prevent the subject
             from participation or interfere with the evaluation of the study objectives;

         11. Females who were pregnant or nursing (breastfeeding) mothers, or females of
             childbearing potential who were sexually active and had not used or did not plan to
             use acceptable birth control measures during the first 3 weeks after vaccination.
             Oral, injected or implanted hormonal contraceptive, diaphragm or condom with
             spermicidal agent or intrauterine device were considered acceptable forms of birth
             control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Balve</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duisberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garmisch-Partenkirchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herborn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Illingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laufach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midlum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olpe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Unterschleißheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2007</study_first_submitted>
  <study_first_submitted_qc>November 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2007</study_first_posted>
  <results_first_submitted>November 21, 2012</results_first_submitted>
  <results_first_submitted_qc>April 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 18, 2013</results_first_posted>
  <disposition_first_submitted>December 13, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>December 13, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 22, 2011</disposition_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 17 centres in Germany.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Egg-derived Vaccine (TIV)</title>
          <description>Subjects received one vaccination of a egg-derived trivalent influenza virus vaccine.</description>
        </group>
        <group group_id="P2">
          <title>Cell Culture-derived Vaccine (cTIV)</title>
          <description>Subjects received one vaccination of a cell-derived trivalent influenza virus vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="396"/>
                <participants group_id="P2" count="1002"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="390"/>
                <participants group_id="P2" count="980"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing primary reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Egg-derived Vaccine (TIV)</title>
          <description>Subjects received one vaccination of a egg-derived trivalent influenza virus vaccine</description>
        </group>
        <group group_id="B2">
          <title>Cell Culture-derived Vaccine (cTIV)</title>
          <description>Subjects received one vaccination of a cell-derived trivalent influenza virus vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="396"/>
            <count group_id="B2" value="1002"/>
            <count group_id="B3" value="1398"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.6" spread="17.3"/>
                    <measurement group_id="B2" value="48.7" spread="16.3"/>
                    <measurement group_id="B3" value="48.3" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="533"/>
                    <measurement group_id="B3" value="739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="469"/>
                    <measurement group_id="B3" value="659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Healthy Adults and Elderly Who Reported Solicited Local and Systemic Adverse Events (AEs) After One Vaccination of TIV or cTIV</title>
        <description>Analysis was performed on a subset of safety population which included the healthy adults (≥18 to ≤60 years) and elderly (≥61 years).</description>
        <time_frame>From Day 1 through Day 7 post-vaccination</time_frame>
        <population>Analysis was done on a subset of safety population (i.e. all subjects in the exposed population who provide postvaccination safety data) which included the healthy adults and elderly.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years years-old received one vaccination of egg-derived influenza virus vaccine</description>
          </group>
          <group group_id="O2">
            <title>cTIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years-old received one vaccination of cell-derived influenza virus vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIV (Elderly)</title>
            <description>Subjects ≥61 years-old received one vaccination of egg-derived influenza virus vaccine</description>
          </group>
          <group group_id="O4">
            <title>cTIV (Elderly)</title>
            <description>Subjects ≥61 years-old received one vaccination of cell-derived influenza virus vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Healthy Adults and Elderly Who Reported Solicited Local and Systemic Adverse Events (AEs) After One Vaccination of TIV or cTIV</title>
          <description>Analysis was performed on a subset of safety population which included the healthy adults (≥18 to ≤60 years) and elderly (≥61 years).</description>
          <population>Analysis was done on a subset of safety population (i.e. all subjects in the exposed population who provide postvaccination safety data) which included the healthy adults and elderly.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="235"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain (N=66,226,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (N=66,226,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=66,226,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=66,226,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=66,226,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=66,226,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating (N=66,226,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=66,226,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38 °C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adults and Elderly With Underlying Medical Conditions Who Reported Solicited Local and Systemic Adverse Events After One Vaccination of TIV or cTIV</title>
        <description>Analysis was performed on a subset of safety population which included the adults (≥18 to ≤60 years) and elderly (≥61 years) with underlying medical conditions.</description>
        <time_frame>From Day 1 through Day 7 post-vaccination</time_frame>
        <population>Analysis was done on the subset of safety population which included the adults and elderly with underlying medical conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years-old received one vaccination of egg-derived influenza virus vaccine</description>
          </group>
          <group group_id="O2">
            <title>cTIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years-old received one vaccination of cell-derived influenza virus vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIV (Elderly)</title>
            <description>Subjects ≥61 years-old received one vaccination of egg-derived influenza virus vaccine</description>
          </group>
          <group group_id="O4">
            <title>cTIV (Elderly)</title>
            <description>Subjects ≥61 years-old received one vaccination of cell-derived influenza virus vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adults and Elderly With Underlying Medical Conditions Who Reported Solicited Local and Systemic Adverse Events After One Vaccination of TIV or cTIV</title>
          <description>Analysis was performed on a subset of safety population which included the adults (≥18 to ≤60 years) and elderly (≥61 years) with underlying medical conditions.</description>
          <population>Analysis was done on the subset of safety population which included the adults and elderly with underlying medical conditions.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="490"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain (N=220,484,98,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (N=220,484,98,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=220,484,98,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=220,484,98,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=220,484,98,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=220,484,98,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating (N=220,484,98,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=220,484,98,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38 °C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages Of Subjects With Underlying Medical Conditions Who Achieved Hemagglutination Inhibition (HI) Titer ≥40 After One Vaccination of TIV or cTIV</title>
        <description>Immunogenicity was measured as the percentage of adults (≥18 to ≤60 years) and elderly (≥61 years) achieving HI titers ≥40 at baseline (Day 1) and three weeks (Day 22) after one vaccination of TIV or cTIV for each of three vaccine strains, evaluated using hemagglutination inhibition (HI) egg-derived antigen assay. This criterion is met according to European (CHMP) guideline if the percentage of subjects achieving HI titers ≥40 is &gt;70% (≥18 to ≤60 years), or &gt;60% (≥61 years).</description>
        <time_frame>Before vaccination (Day 1) and three weeks after vaccination (Day 22)</time_frame>
        <population>Analysis was performed on the immunogenicity subset of adults and elderly with underlying medical conditions (full analysis set [FAS]: all enrolled subjects who received a study vaccine and provided one evaluable serum sample before and after baseline)</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years-old received one vaccination of egg-derived influenza virus vaccine</description>
          </group>
          <group group_id="O2">
            <title>cTIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years-old received one vaccination of cell-derived influenza virus vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIV (Elderly)</title>
            <description>Subjects ≥61 years-old received one vaccination of egg-derived influenza virus vaccine</description>
          </group>
          <group group_id="O4">
            <title>cTIV (Elderly)</title>
            <description>Subjects ≥61 years-old received one vaccination of cell-derived influenza virus vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages Of Subjects With Underlying Medical Conditions Who Achieved Hemagglutination Inhibition (HI) Titer ≥40 After One Vaccination of TIV or cTIV</title>
          <description>Immunogenicity was measured as the percentage of adults (≥18 to ≤60 years) and elderly (≥61 years) achieving HI titers ≥40 at baseline (Day 1) and three weeks (Day 22) after one vaccination of TIV or cTIV for each of three vaccine strains, evaluated using hemagglutination inhibition (HI) egg-derived antigen assay. This criterion is met according to European (CHMP) guideline if the percentage of subjects achieving HI titers ≥40 is &gt;70% (≥18 to ≤60 years), or &gt;60% (≥61 years).</description>
          <population>Analysis was performed on the immunogenicity subset of adults and elderly with underlying medical conditions (full analysis set [FAS]: all enrolled subjects who received a study vaccine and provided one evaluable serum sample before and after baseline)</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="46" upper_limit="65"/>
                    <measurement group_id="O2" value="53" lower_limit="43" upper_limit="62"/>
                    <measurement group_id="O3" value="40" lower_limit="21" upper_limit="61"/>
                    <measurement group_id="O4" value="56" lower_limit="35" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="95" lower_limit="89" upper_limit="98"/>
                    <measurement group_id="O3" value="96" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="86" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="44" upper_limit="63"/>
                    <measurement group_id="O2" value="46" lower_limit="37" upper_limit="55"/>
                    <measurement group_id="O3" value="80" lower_limit="59" upper_limit="93"/>
                    <measurement group_id="O4" value="64" lower_limit="43" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="92" upper_limit="99"/>
                    <measurement group_id="O2" value="87" lower_limit="80" upper_limit="93"/>
                    <measurement group_id="O3" value="100" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O4" value="88" lower_limit="69" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="8" upper_limit="21"/>
                    <measurement group_id="O2" value="16" lower_limit="10" upper_limit="24"/>
                    <measurement group_id="O3" value="40" lower_limit="21" upper_limit="61"/>
                    <measurement group_id="O4" value="28" lower_limit="12" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="68" upper_limit="84"/>
                    <measurement group_id="O2" value="63" lower_limit="53" upper_limit="71"/>
                    <measurement group_id="O3" value="68" lower_limit="46" upper_limit="85"/>
                    <measurement group_id="O4" value="48" lower_limit="28" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages Of Subjects Who Achieved Seroconversion Or Significant Increase In HI Titers After One Vaccination of TIV or cTIV</title>
        <description>Seroconversion or significant increase in HI titer as per CHMP criteria for each of the three strains is defined as the percentage of subjects with a prevaccination HI titer &lt;10 to a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, a ≥4-fold increase in postvaccination HI antibody titer. According to the CHMP criteria, the percentage of subjects achieving seroconversion/significant increase should be &gt;40% (≥18 to ≤60 years) or &gt;30% (≥61 years).</description>
        <time_frame>Three weeks post-vaccination (Day 22)</time_frame>
        <population>Analysis was performed on the immunogenicity subset of adults and elderly with underlying medical conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years-old received one vaccination of egg-derived influenza virus vaccine</description>
          </group>
          <group group_id="O2">
            <title>cTIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years-old received one vaccination of cell-derived influenza virus vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIV (Elderly)</title>
            <description>Subjects ≥61 years-old received one vaccination of egg-derived influenza virus vaccine</description>
          </group>
          <group group_id="O4">
            <title>cTIV (Elderly)</title>
            <description>Subjects ≥61 years-old received one vaccination of cell-derived influenza virus vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages Of Subjects Who Achieved Seroconversion Or Significant Increase In HI Titers After One Vaccination of TIV or cTIV</title>
          <description>Seroconversion or significant increase in HI titer as per CHMP criteria for each of the three strains is defined as the percentage of subjects with a prevaccination HI titer &lt;10 to a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, a ≥4-fold increase in postvaccination HI antibody titer. According to the CHMP criteria, the percentage of subjects achieving seroconversion/significant increase should be &gt;40% (≥18 to ≤60 years) or &gt;30% (≥61 years).</description>
          <population>Analysis was performed on the immunogenicity subset of adults and elderly with underlying medical conditions.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="54" upper_limit="72"/>
                    <measurement group_id="O2" value="65" lower_limit="56" upper_limit="74"/>
                    <measurement group_id="O3" value="72" lower_limit="51" upper_limit="88"/>
                    <measurement group_id="O4" value="60" lower_limit="39" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="52" upper_limit="71"/>
                    <measurement group_id="O2" value="56" lower_limit="46" upper_limit="65"/>
                    <measurement group_id="O3" value="40" lower_limit="21" upper_limit="61"/>
                    <measurement group_id="O4" value="40" lower_limit="21" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="46" upper_limit="64"/>
                    <measurement group_id="O2" value="41" lower_limit="32" upper_limit="50"/>
                    <measurement group_id="O3" value="24" lower_limit="9" upper_limit="45"/>
                    <measurement group_id="O4" value="20" lower_limit="7" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Subjects With Underlying Medical Conditions After One Vaccination of TIV or cTIV</title>
        <description>Immunogenicity was measured as HI geometric mean titers (GMTs) of subjects with underlying conditions, directed against each of three vaccine strains at baseline (Day 1) and three weeks after vaccination (Day 22) in adults (≥18 to ≤60 years) and elderly (≥61 years).</description>
        <time_frame>Before vaccination (Day 1) and three weeks after vaccination (Day 22)</time_frame>
        <population>Analysis was performed on the immunogenicity subset of adults and elderly with underlying medical conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years-old received one vaccination of egg-derived influenza virus vaccine</description>
          </group>
          <group group_id="O2">
            <title>cTIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years-old received one vaccination of cell-derived influenza virus vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIV (Elderly)</title>
            <description>Subjects ≥61 years-old received one vaccination of egg-derived influenza virus vaccine</description>
          </group>
          <group group_id="O4">
            <title>cTIV (Elderly)</title>
            <description>Subjects ≥61 years-old received one vaccination of cell-derived influenza virus vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Subjects With Underlying Medical Conditions After One Vaccination of TIV or cTIV</title>
          <description>Immunogenicity was measured as HI geometric mean titers (GMTs) of subjects with underlying conditions, directed against each of three vaccine strains at baseline (Day 1) and three weeks after vaccination (Day 22) in adults (≥18 to ≤60 years) and elderly (≥61 years).</description>
          <population>Analysis was performed on the immunogenicity subset of adults and elderly with underlying medical conditions.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="27" upper_limit="49"/>
                    <measurement group_id="O2" value="34" lower_limit="25" upper_limit="46"/>
                    <measurement group_id="O3" value="19" lower_limit="11" upper_limit="33"/>
                    <measurement group_id="O4" value="29" lower_limit="17" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354" lower_limit="282" upper_limit="443"/>
                    <measurement group_id="O2" value="308" lower_limit="246" upper_limit="386"/>
                    <measurement group_id="O3" value="132" lower_limit="87" upper_limit="199"/>
                    <measurement group_id="O4" value="158" lower_limit="104" upper_limit="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="23" upper_limit="40"/>
                    <measurement group_id="O2" value="29" lower_limit="22" upper_limit="38"/>
                    <measurement group_id="O3" value="56" lower_limit="32" upper_limit="97"/>
                    <measurement group_id="O4" value="41" lower_limit="23" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224" lower_limit="179" upper_limit="281"/>
                    <measurement group_id="O2" value="156" lower_limit="125" upper_limit="196"/>
                    <measurement group_id="O3" value="174" lower_limit="112" upper_limit="271"/>
                    <measurement group_id="O4" value="145" lower_limit="93" upper_limit="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.35" lower_limit="7.96" upper_limit="11"/>
                    <measurement group_id="O2" value="11" lower_limit="9.24" upper_limit="13"/>
                    <measurement group_id="O3" value="20" lower_limit="13" upper_limit="31"/>
                    <measurement group_id="O4" value="14" lower_limit="8.86" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="46" upper_limit="66"/>
                    <measurement group_id="O2" value="39" lower_limit="32" upper_limit="47"/>
                    <measurement group_id="O3" value="43" lower_limit="26" upper_limit="72"/>
                    <measurement group_id="O4" value="26" lower_limit="16" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio of Subjects With Underlying Medical Conditions After One Vaccination of TIV or cTIV</title>
        <description>Immunogenicity was measured as the geometric mean ratio (GMR), calculated as the ratio of postvaccination to prevaccination HI GMTs for each of the three strains, three weeks after one vaccination (Day 22) of TIV or cTIV. CHMP criteria is considered fulfilled for each of the three strains if the geometric mean increase GMR (Day 22/Day 1) in HI antibody titer is &gt;2.5 (≥18 to ≤60 years) or &gt;2.0 (≥61 Years).</description>
        <time_frame>Three weeks post-vaccination (Day 22)</time_frame>
        <population>Analysis was performed on the immunogenicity subset of adults and elderly with underlying medical conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years-old received one vaccination of egg-derived influenza virus vaccine</description>
          </group>
          <group group_id="O2">
            <title>cTIV (Adults)</title>
            <description>Subjects ≥18 to ≤60 years-old received one vaccination of cell-derived influenza virus vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIV (Elderly)</title>
            <description>Subjects ≥61 years-old received one vaccination of egg-derived influenza virus vaccine</description>
          </group>
          <group group_id="O4">
            <title>cTIV (Elderly)</title>
            <description>Subjects ≥61 years-old received one vaccination of cell-derived influenza virus vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio of Subjects With Underlying Medical Conditions After One Vaccination of TIV or cTIV</title>
          <description>Immunogenicity was measured as the geometric mean ratio (GMR), calculated as the ratio of postvaccination to prevaccination HI GMTs for each of the three strains, three weeks after one vaccination (Day 22) of TIV or cTIV. CHMP criteria is considered fulfilled for each of the three strains if the geometric mean increase GMR (Day 22/Day 1) in HI antibody titer is &gt;2.5 (≥18 to ≤60 years) or &gt;2.0 (≥61 Years).</description>
          <population>Analysis was performed on the immunogenicity subset of adults and elderly with underlying medical conditions.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.65" lower_limit="7.03" upper_limit="13"/>
                    <measurement group_id="O2" value="9" lower_limit="6.55" upper_limit="12"/>
                    <measurement group_id="O3" value="6.96" lower_limit="3.98" upper_limit="12"/>
                    <measurement group_id="O4" value="5.35" lower_limit="3.06" upper_limit="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.35" lower_limit="5.62" upper_limit="9.61"/>
                    <measurement group_id="O2" value="5.32" lower_limit="4.07" upper_limit="6.95"/>
                    <measurement group_id="O3" value="3.12" lower_limit="1.76" upper_limit="5.51"/>
                    <measurement group_id="O4" value="3.58" lower_limit="2.02" upper_limit="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88" lower_limit="4.62" upper_limit="7.49"/>
                    <measurement group_id="O2" value="3.57" lower_limit="2.8" upper_limit="4.54"/>
                    <measurement group_id="O3" value="2.17" lower_limit="1.3" upper_limit="3.64"/>
                    <measurement group_id="O4" value="1.92" lower_limit="1.15" upper_limit="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Reported At Least One Reactogenicity Sign After One Vaccination of TIV or cTIV</title>
        <description>Safety was assessed as the number of all subjects who reported at least one sign of reactogenicity after one vaccination of egg-derived (TIV) or cell culture-derived (cTIV) influenza virus vaccine from Day 1 through Day 7 post-vaccination.</description>
        <time_frame>From Day 1 up to and including Day 7 post-vaccination</time_frame>
        <population>Analysis was performed on the safety dataset, i.e. all subjects in the exposed set who provided post-baseline safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Egg-derived Vaccine (TIV)</title>
            <description>Subjects received one vaccination of a egg-derived trivalent influenza virus vaccine</description>
          </group>
          <group group_id="O2">
            <title>Cell Culture-derived Vaccine (cTIV)</title>
            <description>Subjects received one vaccination of a cell-derived trivalent influenza virus vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Reported At Least One Reactogenicity Sign After One Vaccination of TIV or cTIV</title>
          <description>Safety was assessed as the number of all subjects who reported at least one sign of reactogenicity after one vaccination of egg-derived (TIV) or cell culture-derived (cTIV) influenza virus vaccine from Day 1 through Day 7 post-vaccination.</description>
          <population>Analysis was performed on the safety dataset, i.e. all subjects in the exposed set who provided post-baseline safety data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="1001"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any reaction - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any reaction - None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any reaction - Other than severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any reaction - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reaction - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reaction - None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274"/>
                    <measurement group_id="O2" value="654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reaction - Other than severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reaction - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction - None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction - Other than severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period (day 1 to day 181).</time_frame>
      <desc>All enrolled subjects met entry criteria with one exception. One subject was enrolled and randomized to the CTIV group but did not receive the study vaccine due to a protocol deviation. This subject was excluded from both the safety and immunogenicity analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>Egg-derived Vaccine (TIV)</title>
          <description>Subjects received one vaccination of a egg-derived trivalent influenza virus vaccine</description>
        </group>
        <group group_id="E2">
          <title>Cell Culture-derived Vaccine (cTIV)</title>
          <description>Subjects received one vaccination of a cell-derived trivalent influenza virus vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Chest Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Aortic Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Aortic Valve Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Hearing Loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoidal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Device Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal Bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Optic Neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethral Caruncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="568" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="330" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="1001"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="198" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1001"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Because cTIV was not available, the second part of the study was not performed. In addition, as deviations from protocol procedures and GCP were identified at some sites, data collected for this study were not used to support licensure of cTIV.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

